Published in Trends Biotechnol on June 01, 1994
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells. Proc Natl Acad Sci U S A (2007) 2.78
Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov (2010) 2.69
Metabolic labeling of sialic acids in living animals with alkynyl sugars. Angew Chem Int Ed Engl (2009) 1.53
5-Aza-2'-deoxycytidine increases sialyl Lewis X on MUC1 by stimulating β-galactoside:α2,3-sialyltransferase 6 gene. Int J Biochem Cell Biol (2010) 1.48
HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br J Cancer (2000) 1.38
Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers. Proc Natl Acad Sci U S A (2014) 1.02
Antibody recognition of a unique tumor-specific glycopeptide antigen. Proc Natl Acad Sci U S A (2010) 1.00
Glycoproteomics enabled by tagging sialic acid- or galactose-terminated glycans. Glycobiology (2012) 0.93
Synthesis of glycosylated β³-homo-threonine conjugates for mucin-like glycopeptide antigen analogues. Beilstein J Org Chem (2010) 0.85
One-pot multi-enzyme (OPME) chemoenzymatic synthesis of sialyl-Tn-MUC1 and sialyl-T-MUC1 glycopeptides containing natural or non-natural sialic acid. Bioorg Med Chem (2013) 0.80
Dynamic Sialylation in Transforming Growth Factor-β (TGF-β)-induced Epithelial to Mesenchymal Transition. J Biol Chem (2015) 0.77
From imino sugars to cancer glycoproteins. Glycoconj J (2003) 0.77
Click Triazoles for Bioconjugation. Top Heterocycl Chem (2012) 0.76
Development of a novel bi-specific monoclonal antibody approach for tumour targeting. Br J Cancer (1999) 0.75
Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours. Lancet (1982) 2.51
A monoclonal antibody that detects HLA-D region antigen in routinely fixed, wax embedded sections of normal and neoplastic lymphoid tissues. J Clin Pathol (1985) 2.00
Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J Nucl Med (1990) 1.76
Use of two epithelium-specific monoclonal antibodies for diagnosis of malignancy in serous effusions. Lancet (1982) 1.76
Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res (1986) 1.39
Alternative to toxicity and dosimetry of Y-90 labeled antibody. Int J Radiat Oncol Biol Phys (1989) 1.39
Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med (1988) 1.34
E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int J Cancer (1995) 1.25
Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res (1986) 1.24
An immunohistological study of testicular germ cell tumours using two different monoclonal antibodies against placental alkaline phosphatase. Br J Cancer (1984) 1.19
Indium-111 labelled monoclonal antibody to placental alkaline phosphatase in in the detection of neoplasms of testis, ovary, and cervix. Lancet (1985) 1.17
A study of in vivo immune complex formation and clearance in man. J Immunol (1990) 1.14
Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen. Br Med J (Clin Res Ed) (1985) 1.11
Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer (1990) 1.11
Preexisting human anti-murine immunoglobulin reactivity due to polyclonal rheumatoid factors. Cancer Res (1987) 1.07
Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet (1988) 1.07
Antibody guided lymphangiography in the staging of cervical cancer. Br J Cancer (1985) 1.04
Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy? Br J Cancer (1989) 1.00
Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry. Int J Cancer Suppl (1988) 0.98
Site-specific polysialylation of an antitumor single-chain Fv fragment. Bioconjug Chem (2009) 0.97
Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer (1993) 0.97
Detection of human cancer in an animal model using radio-labelled tumour-associated monoclonal antibodies. Br J Cancer (1982) 0.94
Monoclonal antibody assay of serum placental alkaline phosphatase in the monitoring of testicular tumours. Br J Cancer (1985) 0.93
Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl (1990) 0.93
Antibody guided targeting of non-small cell lung cancer using 111In-labeled HMFG1 F(ab')2 fragments. Cancer Res (1988) 0.92
Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res (1999) 0.91
Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res (1992) 0.91
Enhancement of monoclonal antibody uptake in human colon tumor xenografts following irradiation. Cancer Res (1990) 0.90
Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer. Int J Cancer (1991) 0.90
Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med (1998) 0.89
Ovarian cancer: diagnosis using 123I monoclonal antibody in comparison with surgical findings. Nucl Med Commun (1984) 0.89
Redesigned anti-human placental alkaline phosphatase single-chain Fv: soluble expression, characterization and in vivo tumour targeting. Protein Eng (1997) 0.88
Antibody-guided radiolocalisation of tumours in patients with testicular or ovarian cancer using two radioiodinated monoclonal antibodies to placental alkaline phosphatase. Br J Radiol (1986) 0.88
Effect of tumour necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumour xenograft model. Br J Cancer (1995) 0.88
Localization of monoclonal antibody AUA1 and its F(ab')2 fragments in human tumour xenografts: an autoradiographic and immunohistochemical study. Int J Cancer Suppl (1988) 0.87
Applications of monoclonal antibodies in clinical oncology. Immunol Today (1994) 0.87
Effect of polarity and differentiation on antibody localization in multicellular tumour spheroid and xenograft models and its potential importance for in vivo immunotargeting. Int J Cancer (1989) 0.87
Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. Oncol Rep (1998) 0.87
Radioimmunodiagnosis of ovarian cancer using 123I-labelled, tumor-associated monoclonal antibodies. Cancer Detect Prev (1984) 0.87
A recombinant single chain antibody interleukin-2 fusion protein. Br J Cancer (1993) 0.86
A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer. Br J Cancer (1986) 0.86
A low pH enzyme linked immunoassay using two monoclonal antibodies for the serological detection and monitoring of breast cancer. Br J Cancer (1986) 0.85
In vitro cytotoxicity following specific activation of amygdalin by beta-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. Int J Cancer (1998) 0.85
Intraperitoneal radioimmunotherapy for ovarian cancer. Br J Obstet Gynaecol (1989) 0.85
Radioimmunodetection of Cancer. Eur J Cancer Clin Oncol (1982) 0.83
Localization of biotinylated monoclonal antibody in nude mice bearing subcutaneous and intraperitoneal human tumour xenografts. Int J Cancer Suppl (1988) 0.83
Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1. Br J Cancer (2005) 0.83
Tumour-associated monoclonal antibodies for the diagnosis and assessment of ovarian cancer. Br J Obstet Gynaecol (1987) 0.83
Construction, characterisation and kinetics of a single chain antibody recognising the tumour associated antigen placental alkaline phosphatase. Br J Cancer (1993) 0.82
123I radioiodinated antibody imaging of occult ovarian cancer. Cancer (1985) 0.81
Genetic delivery of enzymes for cancer therapy. Gene Ther (1995) 0.81
Enhancement by gamma-interferon of in vivo tumor radiolocalization by a monoclonal antibody against HLA-DR antigen. Cancer Res (1986) 0.81
Tumour imaging using an improved method of DTPA-coupled monoclonal antibodies radiolabelled with metallic radionuclides. Lancet (1984) 0.81
Antibody-guided irradiation of malignant ascites in ovarian cancer: a new therapeutic method possessing specificity against cancer cells. Obstet Gynecol (1986) 0.80
Immunolocalisation of testicular tumours using radiolabelled monoclonal antibody to placental alkaline phosphatase. J Nucl Med Allied Sci (1991) 0.80
A recombinant cytotoxic chimera based on mammalian deoxyribonuclease-I. Int J Cancer (2000) 0.79
Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions. Br J Cancer Suppl (1990) 0.79
Targeting enzymes for cancer therapy: old enzymes in new roles. Br J Cancer (1994) 0.79
Preparation and use of DTPA-coupled antitumor antibodies radiolabeled with yttrium-90. Targeted Diagn Ther (1988) 0.79
Deoxyribonuclease I (DNAse I). A novel approach for targeted cancer therapy. Cell Biophys (1994) 0.79
Uptake and distribution of specific and control monoclonal antibodies in subcutaneous xenografts following intratumor injection. Cancer Res (1991) 0.79
Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins. Br J Cancer (1998) 0.79
The role of monoclonal antibodies in tumour diagnosis. Cancer Treat Rev (1986) 0.79
Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. Br J Cancer (1991) 0.79
DNA vaccination for cancer treatment. Gene Ther (1995) 0.79
Improving tumour targeting and decreasing normal tissue uptake by optimizing the stoichiometry of a two-step biotinylated-antibody/streptavidin-based targeting strategy: studies in a nude mouse xenograft model. Int J Cancer (1998) 0.79
Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. J Nucl Med (1995) 0.78
Genetically engineered antibodies for diagnostic pathology. Hum Pathol (1994) 0.78
Preparation and in vivo study of 124I-labelled monoclonal antibody H17E2 in a human tumour xenograft model. A prelude to positron emission tomography (PET). Br J Cancer Suppl (1990) 0.78
Use of monoclonal antibodies for the diagnosis and treatment of bladder cancer. Hybridoma (1999) 0.78
Direct technetium-99m labeling of three anticancer monoclonal antibodies: stability, pharmacokinetics and imaging. J Nucl Med (1995) 0.78
Targeted delivery of biologic and other antineoplastic agents. Curr Opin Oncol (1992) 0.78
Enhanced in vivo immunogenicity induced by an antibody to the IL-4 receptor-associated gp200-MR6 molecule. Scand J Immunol (1996) 0.78
Antibody-guided diagnosis and therapy of malignant lesions. Int J Cancer Suppl (1988) 0.78
Immune responses in advanced colorectal cancer following repeated intradermal vaccination with the anti-CEA murine monoclonal antibody, PR1A3: results of a phase I study. Int J Colorectal Dis (2005) 0.77
Monoclonal antibody targeting of ovarian carcinoma. Oncology (1998) 0.77
Construction, expression and characterisation of a single chain anti-tumour antibody (scFv)-IL-2 fusion protein. Ann Oncol (1995) 0.77
Recent developments in radioimmunotherapy. Clin Oncol (R Coll Radiol) (1994) 0.77
Malignant ascites: review of the literature, and an update on monoclonal antibody-targeted therapy. Eur J Obstet Gynecol Reprod Biol (1989) 0.77
Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer (1994) 0.77
Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Cancer Res (1995) 0.77
An overview of radioimmunotherapy. Cancer Immunol Immunother (1991) 0.77
Serum levels of c-myc and c-ras oncogene products in normal subjects and in patients with neoplastic and non neoplastic conditions. Int J Biol Markers (1988) 0.76
Radioimmunoscintigraphy in patients with ovarian cancer. Acta Oncol (2001) 0.76
Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res (1987) 0.76
Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer (1994) 0.76
Comparison of two combination chemotherapy regimens in advanced colorectal cancer. Br Med J (1980) 0.75
Conjugation of monoclonal antibodies to a synthetic peptide substrate for protein kinase: a method for labelling antibodies with 32P. Br J Cancer (1988) 0.75
Accumulation characteristics of human colon carcinomas after monoclonal antibody ex vivo perfusion. Br J Cancer Suppl (1990) 0.75
Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate. Br J Cancer (1991) 0.75
Kinetics, quantitative analysis and radioimmunolocalization using indium-111-HMFG1 monoclonal antibody in patients with breast cancer. Br J Cancer (1989) 0.75
Imaging thrombus with radiolabelled monoclonal antibody to platelets. Br Med J (Clin Res Ed) (1986) 0.75
The role of humoral and cellular immunity in patients developing human anti-murine immunoglobulin antibody responses after radioimmunotherapy. Br J Cancer Suppl (1990) 0.75
Immunosuppression by immunoglobulin deaggregation is not effective in reducing the anti-xenogeneic immunoglobulin response: experimental and clinical studies. Br J Cancer (1989) 0.75
Development of a novel bi-specific monoclonal antibody approach for tumour targeting. Br J Cancer (1999) 0.75
Seminoma in Marfan's syndrome. Postgrad Med J (1979) 0.75
Radioimmunoscintigraphy in patients with ovarian cancer. Acta Oncol (1999) 0.75
Lymphocyte targeting with 111In-labelled monoclonal antibodies. Int J Cancer Suppl (1988) 0.75
Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas. Int J Cancer (1993) 0.75